Fexofenadine Hydrochloride bid

Phase 2Small molecule

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Fexofenadine Hydrochloride bid is one of 2 small molecule programs targeting ST-segment Elevation Myocardial Infarction (STEMI). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ST-Segment Elevation Myocardial Infarction (STEMI)Recruiting

ST-Segment Elevation Myocardial Infarction (STEMI)Phase 2

Recruiting

Competition

Competitive Landscape

1 competitor in ST-Segment Elevation Myocardial Infarction (STEMI)

#DrugCompanyPhaseTrials

Fexofenadine Hydrochloride

UUniversity Ghent

Phase 2

1 2

Fexofenadine Hydrochloride bid

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

ST-Segment Elevation Myocardial Infarction (STEMI)

NCT06548204

Clinical

Trials by Indication[1]

ST-segment Elevation Myocardial Infarction (STEMI)1 trial

Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06548204·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fexofenadine Hydrochloride bid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fexofenadine Hydrochloride bid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fexofenadine Hydrochloride bid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital, School of Medicine, Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Fexofenadine Hydrochloride bid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

ST-segment Elevation Myocardial Infarction (STEMI)1 trial

References

Drug Info

Quick Facts

Related News